思创医惠(300078) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 4.18% to CNY 30,587,200.89 for the reporting period[9] - Operating revenue for the reporting period was CNY 309,492,893.38, a decline of 10.06% year-on-year[9] - The net profit after deducting non-recurring gains and losses dropped by 95.95% to CNY 1,211,099.53[9] - Basic earnings per share decreased by 10.89% to CNY 0.0352[9] - The weighted average return on equity was 1.04%, down by 0.41% compared to the previous year[9] - Total operating revenue for Q3 2020 was CNY 309,492,893.38, a decrease from CNY 344,101,775.15 in the previous period[38] - Net profit for Q3 2020 was CNY 31,335,774.64, slightly down from CNY 31,736,419.41 in the same period last year[40] - The company reported a total comprehensive income of CNY 27,030,357.09 for Q3 2020, down from CNY 31,565,980.50 in the previous year[41] Assets and Liabilities - Total assets increased by 11.58% to CNY 4,713,652,580.08 compared to the end of the previous year[9] - Total current assets increased to CNY 2,487,003,673.96 as of September 30, 2020, up from CNY 2,255,461,284.14 at the end of 2019, representing an increase of approximately 10.25%[30] - Non-current assets totaled CNY 2,226,648,906.12, an increase from CNY 1,969,155,467.77, marking a growth of approximately 13.09%[31] - Total liabilities increased to CNY 1,616,051,784.69 from CNY 1,280,490,427.53, which is an increase of approximately 26.23%[32] - The company's total equity reached CNY 3,097,600,795.39, up from CNY 2,944,126,324.38, representing an increase of approximately 5.21%[33] - Total liabilities reached CNY 1,280,490,427.53, with current liabilities at CNY 1,011,384,916.44 and non-current liabilities at CNY 269,105,511.09[63] Cash Flow - The company reported a net cash flow from operating activities of CNY -31,574,966.66, an increase of 77.72% year-to-date[9] - Net cash flow from operating activities improved by 77.72% to -¥31,574,966.66 from -¥141,699,636.49 due to optimization of the business model[18] - Cash inflow from financing activities was CNY 761,123,862.83, compared to CNY 403,882,800.00 in the previous period, leading to a net cash flow of CNY 82,548,100.36[56] - The cash inflow from operating activities totaled CNY 1,181,259,933.15, an increase from CNY 1,003,030,301.92 in the previous period[55] Shareholder Information - The total number of shareholders at the end of the reporting period was 48,830[13] - The largest shareholder, Hangzhou Sichuang Medical Technology Group Co., Ltd., held 10.46% of the shares[13] Research and Development - Research and development expenses increased by 21.11% to ¥122,645,992.93 from ¥101,264,304.18 due to the rise in R&D projects including the main data management platform software[17] - Research and development expenses for Q3 2020 were CNY 57,845,914.98, compared to CNY 36,202,396.48 in the previous year, reflecting a significant increase[39] Government Support - The company received government subsidies amounting to CNY 51,197,307.45 during the reporting period[10] Other Financial Metrics - Management expenses increased by 45.23% to ¥140,181,127.43 from ¥96,521,102.01 primarily due to increased equity incentive expenses[17] - Other income rose by 101.71% to ¥65,546,199.09 from ¥32,494,497.41 due to enhanced innovation capabilities leading to special funding subsidies[17] - Long-term borrowings increased by 95.20% to ¥524,477,568.41 from ¥268,687,211.09 as part of the company's financing structure optimization[17]